證監會同意中芯國際科創板IPO註冊
uSMART友信智投6月29日消息,證監會同意以下企業科創板首次公開發行股票註冊:中芯國際積體電路製造有限公司、安徽大地熊新材料股份有限公司。
中芯國際科創板發行招股書顯示,公司此次擬募資金額達200億元,是科創板開板一年多以來首發募資最多的新股,募資規模排名第二的為去年首批在科創板上市的中國通號,其首發募資額為105億元。
公開信息顯示,中芯國際成立於2000年,面向全球客戶提供0.35微米到14納米晶圓代工與技術服務,公司2019年在全球晶圓代工市場市占率約4.87%,位列全球第五。2010年後公司戰略性放棄記憶體生產,以生產邏輯晶片為主。
中芯國際港股今年以來表現強勢,年初至今累計漲幅達122%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.